Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 27, 2016

Primary Completion Date

December 31, 2021

Study Completion Date

March 31, 2022

Conditions

Fallopian Tube CarcinomaRecurrent Ovarian CancerPrimary Peritoneal CarcinomaRecurrent Endometrial Cancer

Interventions

DRUG

Lenvatinib Mesylate

Given PO

DRUG

Paclitaxel

Given IV

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors

collaborator

Eisai Inc.

INDUSTRY

lead

Floor Backes

OTHER

NCT02788708 - Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer | Biotech Hunter | Biotech Hunter